Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07262619 · ClinicalTrials.gov registry record · Phase 1
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
A Phase 1 study of Endometrial Cancer and Advanced Solid Tumors, sponsored by Eikon Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
- 10
- Study locations
NCT07262619: Recruiting Phase 1 study of Endometrial Cancer and Advanced Solid Tumors, sponsored by Eikon Therapeutics.
NCT07262619 is a Phase 1 study of Endometrial Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Eikon Therapeutics. The registered enrollment target is 160 participants, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (69% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07262619, a Phase 1 study of Endometrial Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Eikon Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
- 10
- Study locations
Study Summary
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Primary Outcome
A DLT is a protocol-defined adverse event occurring during the DLT observation period.
Conditions Studied
Interventions
- DRUG EIK1005
- DRUG pembrolizumab (KEYTRUDA® )
Study Locations (10)
Victoria
- Grampians Health - Ballarat
- Chris O'Brien Lifehouse (Sydney Cancer Centre) - Camperdown
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital - Frankston
- Peninsula and Southeast Oncology (PASO) Medical - Frankston
New South Wales
- GenesisCare North Shore (Oncology) - Saint Leonards
- Calvary Mater Newcastle Hospital - Waratah
New Jersey
- Morristown Medical Center - Morristown
New York
- Memorial Sloan Kettering Cancer Center (MSKCC) - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
Other
- Health New Zealand - Wellington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-01-22 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT07262619 shows while recruiting
NCT07262619 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 523-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (69% lower).
The record links to 7 conditions, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which EIK1005 is the first listed.
NCT07262619 lists 10 locations in 6 states (Victoria, New South Wales, New Jersey).
Frequently Asked Questions
What is clinical trial NCT07262619 about?
NCT07262619 is a clinical study titled "EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors". The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
What is the current status of trial NCT07262619?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2026-01-22. Estimated completion is 2029-03.
What conditions does trial NCT07262619 study?
This clinical trial studies the following conditions: Endometrial Cancer, Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H or dMMR Advanced Solid Tumors.
What interventions are being tested in trial NCT07262619?
The interventions under investigation include: EIK1005 (DRUG), pembrolizumab (KEYTRUDA® ) (DRUG).
Who is sponsoring clinical trial NCT07262619?
This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07262619 being conducted?
This trial has 10 study locations across New Jersey, New York, Texas, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07262619's enrollment target sits among peer trials
160 76th of 181 higher than 106 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI